The article "The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins" by Kyriacos Felekkis and Christos Papaneophytou explores the potential of integrating circulating microRNAs (c-miRNAs), cell-free DNAs (cfDNAs), and proteins as biomarkers for disease diagnosis and prognosis. The authors highlight the advantages of c-miRNAs, including their stability, specificity, and non-invasive detection, while acknowledging the limitations of single-marker diagnostics. They argue that a multi-analyte approach offers significant advantages over single-analyte methods, particularly in early disease detection and personalized medicine. The review discusses the challenges and future directions in integrating these biomarkers into clinical practice, emphasizing the need for standardized protocols and further validation studies. The authors conclude that the collaborative power of c-miRNAs with other biomarkers represents a promising frontier in the comprehensive understanding and management of complex diseases, but several challenges must be addressed before this approach can be widely adopted.The article "The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins" by Kyriacos Felekkis and Christos Papaneophytou explores the potential of integrating circulating microRNAs (c-miRNAs), cell-free DNAs (cfDNAs), and proteins as biomarkers for disease diagnosis and prognosis. The authors highlight the advantages of c-miRNAs, including their stability, specificity, and non-invasive detection, while acknowledging the limitations of single-marker diagnostics. They argue that a multi-analyte approach offers significant advantages over single-analyte methods, particularly in early disease detection and personalized medicine. The review discusses the challenges and future directions in integrating these biomarkers into clinical practice, emphasizing the need for standardized protocols and further validation studies. The authors conclude that the collaborative power of c-miRNAs with other biomarkers represents a promising frontier in the comprehensive understanding and management of complex diseases, but several challenges must be addressed before this approach can be widely adopted.